Cytokines in the Management of High Risk or Advanced Breast Cancer: An Update and Expectation (Articolo in rivista)

Type
Label
  • Cytokines in the Management of High Risk or Advanced Breast Cancer: An Update and Expectation (Articolo in rivista) (literal)
Anno
  • 2009-01-01T00:00:00+01:00 (literal)
Alternative label
  • A. Carpi*1; A. Nicolini 2; A. Antonelli 2; P. Ferrari 2; G. Rossi 3 (2009)
    Cytokines in the Management of High Risk or Advanced Breast Cancer: An Update and Expectation
    in Current cancer drug targets (Print); Bentham Science Publishers Ltd., Sharjah (Emirati Arabi Uniti)
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • A. Carpi*1; A. Nicolini 2; A. Antonelli 2; P. Ferrari 2; G. Rossi 3 (literal)
Pagina inizio
  • 888 (literal)
Pagina fine
  • 903 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 9 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali
  • 16 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 8 (literal)
Note
  • ubMe (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • 1Department of Reproduction and Ageing, University of Pisa, Pisa, Italy; 2Department of Internal Medicine, Universityof Pisa, Pisa, Italy; 3Unit of Epidemiology and Biostatistics, Institute of Clinical Physiology, CNR., Pisa, Italy (literal)
Titolo
  • Cytokines in the Management of High Risk or Advanced Breast Cancer: An Update and Expectation (literal)
Abstract
  • Some cytokines (interleukin (IL)-2, IL-11, transforming growth factor(TGF)?) stimulate, while others (IL-12, IL-18, Interferons (IFNs)) inhibit breast cancer proliferation and/or invasion. So far IL-2, IFN?, IFN? and occasionally IFN?, IL-6, IL-12 have been used for the treatment of advanced breast cancer either to induce or increase hormone sensitivity and/or to stimulate cellular immunity. Only two long term pilot studies suggest that IL-2 and IFN? can improve clinical benefit and/or overall survival of metastatic breast cancer patients with minimal residual disease after chemotherapy or with disseminate disease non progressing during endocrine therapy. These results have been interpreted assuming that tumour microenvironment impairs the immune system of the host. Consequently, minimal disease or intense cytostatic effects following chemo or endocrine therapy, respectively, permit the patient's immune system to respond to the stimulatory effect of the cytokines. Therefore a prospective, phase III, randomised, simple blind trial has been planned. The aim is to assess whether the addition of IFN? and IL-2 to standard hormone therapy in postmenopausal patients with metastatic breast cancer and positive or unknown positive receptors prolongs the clinical benefit and survival since the metastatic diagnosis and the beginning of first line salvage antiestrogen therapy, compared with the results achieved with standard hormone therapy alone. If this immunotherapy prolongs survival of endocrine dependent metastatic breast cancer patients, IL-2 and IFN? can also be evaluated as adjuvant treatment of patients with positive estrogen receptors. (literal)
Editore
Prodotto di
Autore CNR
Insieme di parole chiave

Incoming links:


Autore CNR di
Prodotto
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
Editore di
Insieme di parole chiave di
data.CNR.it